Brazilian cancer centers test new biosimilar treatment in real patients
NCT ID NCT06808685
Summary
This study is observing how a biosimilar version of the cancer drug bevacizumab works in real-world treatment of advanced colorectal cancer in Brazil. Researchers will follow 133 adult patients with metastatic colorectal cancer who are receiving this drug as part of their first-line treatment. The study will track how long the treatment works, survival rates, side effects, and how patients function daily over a 24-month period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Instituto Dor de Pesquisa E Ensino
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.